Pharmaceutical intelligence for Shanghai Haiyan Pharmaceutical with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalJuly 3, 2026

Phase 1 Study of YZJ-5053 Tablets in Advanced Solid Tumors Initiated

A Phase 1 clinical trial is underway to assess the safety and efficacy of YZJ-5053 tablets in patients with advanced solid tumors.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 3, 2026

Phase 1 Study of YZJ-5053 Tablets in Advanced Solid Tumors Initiated

A Phase 1 clinical trial is underway to assess the safety and efficacy of YZJ-5053 tablets in patients with advanced solid tumors.

Competitive activity

No signals indexed for this entity yet.

Assets

YZJ-5053 →

Therapeutic areas

Oncology →

Small Molecule →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.